Coronary artery bypass surgery management of hyperlipidemia



==ACCF/AHA Guidelines for Management of Hyperlipidemia in Patients Undergoing CABG == {{cquote|

Class I
1. All patients undergoing CABG should receive statin therapy, unless contraindicated. (Level of Evidence: A)

2. In patients undergoing CABG, an adequate dose of statin should be used to reduce LDL cholesterol to less than 100 mg/dL and to achieve at least a 30% lowering of LDL cholesterol. (Level of Evidence: C)

Class IIa
1. In patients undergoing CABG, it is reasonable to treat with statin therapy to lower the LDL cholesterol to less than 70 mg/dL in very high-risk* patients. (Level of Evidence: C)

2. For patients undergoing urgent or emergency CABG who are not taking a statin, it is reasonable to initiate high-dose statin therapy immediately. (Level of Evidence: C)

Class III: HARM
1. Discontinuation of statin or other dyslipidemic therapy is not recommended before or after CABG in patients without adverse reactions to therapy. (Level of Evidence: B)}}

Guidelines Resources

 * 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines